David Gruben

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

Roy Fleischmann, Joel M. Kremer, John J. Cush et al. · New England Journal of Medicine · 2012 · 1K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen et al. · New England Journal of Medicine · 2012 · 939 citations · Full text

Medicine, Immunology, Pharmacology +13

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

Eun Bong Lee, Roy Fleischmann, Stephen Hall et al. · New England Journal of Medicine · 2014 · 774 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

Gerd R Burmester, Ricardo Blanco, Christina Charles‐Schoeman et al. · The Lancet · 2013 · 720 citations

Medicine, Pharmacology, Pharmacotherapy +12

Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study

Désirée van der Heijde, Yoshiya Tanaka, Roy Fleischmann et al. · Arthritis & Rheumatism · 2013 · 582 citations

Medicine, Internal Medicine, Pharmacotherapy +14